Figure 8.
Anti-HMGB1 impaired the ability of HMGB1-stimulated BMDCs to prime Th17 responses in vivo. Mice received an intratracheal (i.t.) injection of 2 × 106 PBS-treated, nonpulsed DCs (PBS/DCs), rHMGB1-treated, OVA-pulsed DCs (rHMGB1/OVA-DCs), or rHMGB1 plus anti-HMGB1-treated, OVA-pulsed DCs (rHMGB1 + anti-HMGB1/OVA-DCs). The mice were then exposed to OVA aerosols on days 10–12. (a) The total and differential cells counts and (b) cytokine profiles in the BALF were assessed 24 h after the final OVA exposure. The values represent the means ± standard deviations (n = 5). *P < 0.05 and **P < 0.01 compared with the asthma group.